BackgroundThe benefit of first-line use of sodium-dependent glucose transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus (T2DM) with low risk of cardiovascular diseases are not clear. MethodsPubMed. EMBASE and Cochrane Library databases were searched to identify eligible randomized controlled trials. We used the odds rati... https://www.shopmillensiumers.shop/product-category/tobacco-accessories/